Sunesis Pharmaceuticals (SNSS) Lowered to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a strong-buy rating to a hold rating in a report published on Thursday.

According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “

Other analysts have also issued research reports about the company. ValuEngine raised Sunesis Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, January 2nd. HC Wainwright started coverage on Sunesis Pharmaceuticals in a research note on Thursday, December 20th. They issued a neutral rating and a $0.50 price target for the company. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Sunesis Pharmaceuticals has an average rating of Hold and an average target price of $1.75.

Shares of SNSS stock opened at $0.73 on Thursday. Sunesis Pharmaceuticals has a 52 week low of $0.20 and a 52 week high of $7.69. The firm has a market capitalization of $18.33 million, a P/E ratio of -0.51 and a beta of 2.57.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. As a group, analysts expect that Sunesis Pharmaceuticals will post -0.81 EPS for the current fiscal year.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

See Also: What is the Quick Ratio?

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.